22 September 2022 – Notice of R&D Update Meeting

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Notice of R&D Update Meeting

Brighton, United Kingdom – 22 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that it will host an R&D Update meeting for analysts and investors on Tuesday, 18 October 2022 at 1.00 pm BST / 8.00 am EST.

The R&D Update meeting will be held in person at finnCap Ltd, 1 Bartholomew Close, London, EC1A 7BL, with the option of virtual attendance via the Investor Meet platform.

The meeting, which is scheduled to last around two hours, will include an update on the status of NTCD-M3 and XF-73, the Company’s two lead clinical programmes, by Dr Yuri Martina, Chief Medical Officer, and Dr Stephanie Bewick, Chief Business Officer, as well as a short update on its earlier pipeline assets.

In addition, there will be presentations by senior Key Opinion Leaders on:

  • Recurrence in C. difficile infection (CDI) – the unmet medical need by Professor Mark Wilcox, Consultant Microbiologist and Head of R&D in Microbiology at the Leeds Teaching Hospital and member of Destiny Pharma’s Scientific Advisory Board.
  • Surgical site infection in breast reconstruction surgery – a Plastic Surgeon’s view by Dr Alex Mericli, Associate Professor and Plastic Surgeon at MD Anderson Cancer Center.

There will be an opportunity for Q&A with the speakers and Destiny Pharma’s management team.

Prior registration for the event is required. To attend in person please contact RD@destinypharma.com. To attend virtually, investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via:

https://www.investormeetcompany.com/destiny-pharma-plc/register-investor

Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited to the event. Questions can be submitted pre-event via the Investor Meet Company Dashboard up until 1.00 pm BST / 8.00 am EST the day before the meeting, or at any time during the live presentation.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500

Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus
+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com

MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12

Stern IR – US
Janhavi Mohite
+1-212-362-1200
Janhavi.Mohite@sternir.com

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com.

 

Notes to Editors

Mark H Wilcox, MD, FRCPath
Professor Mark Wilcox is an expert in infectious disease and currently serves in several substantive roles including: a Consultant Microbiologist and Head of Research and Development in Microbiology at the Leeds Teaching Hospitals (LTHT).  Professor Wilcox is also the Infection Lead of Leeds NIHR Diagnostic Technologies Medical Technology and In Vitro Diagnostic Co-operative; Professor of Medical Microbiology at the University of Leeds; National Clinical Director of AMR for NHS Improvement/England (NHSE/I); and Lead on Clostridium difficile for Public Health England .

He serves in multiple advisory roles, including to UK SAGE (COVID-19), as co-chair of the UK Technical Validation Group for COVID-19 tests, as a medical advisor to the National Infection Prevention & Control Lead (NHSE/I), the Medical Research Council’s Infection and Immunity Panel, as Chair of PHE’s Rapid Review Panel  and member of the UK NHS Antimicrobial Resistance Programme Board. Professor Wilcox was formerly the Director of Infection Prevention (4 years), Infection Control Doctor (8 years), and Clinical Director of Pathology (6 years) at LTHT and Head of Microbiology (15 years).

Dr Alex Mericli
Dr Mericli is an Associate Professor of Plastic Surgery at The University of Texas MD Anderson Cancer Center. He completed his plastic surgery residency at the University of Virginia, followed by a fellowship in microvascular and reconstructive surgery at MD Anderson. Dr Mericli is interested in all aspects of reconstructive surgery with particular attention to breast, head and neck, and trunk reconstruction. He is dedicated to surgical research and education, having received numerous awards and has authored or co-authored over 70 peer-reviewed articles and book chapters on various plastic surgery topics and lectured nationally and internationally on his research.

Dr Mericli also serves as the Medical Director for Perioperative Surgical Services at MD Anderson. In this role he leads a number of efforts and strategies aimed at optimizing the efficiency of the main and Mays operating rooms. Dr Mericli is a champion of value-based care – both in theory and in practice – and has published a number of articles detailing the cost-effectiveness of several different plastic surgery procedures and technology.

Note to shareholders

Please note the following in relation to the upcoming General Meeting on 26 November 2020:

(i) the entitlement time and date is 18:30 p.m. on 24 November 2020 (please ignore the typographical error in note 11 to the Notice of General Meeting which references 6 November 2020),

(ii) Proxy forms should be received by 24 November 2020. For the avoidance of doubt, any proxy forms received up to 10.00 a.m. on 25 November 2020 will also be valid.